Admission Glucose in ACS Linked to Adverse Events

Higher fasting glucose linked to in-hospital mortality risk in acute coronary syndrome patients

18 aug 2009-- Elevated fasting glucose upon admission for acute coronary syndrome is associated with in-hospital and six-month adverse events, according to research published Aug. 15 in the American Journal of Cardiology.

Louis Kolman, M.D., of the University of Michigan Health System in Ann Arbor, and colleagues analyzed data from 1,541 patients admitted with a diagnosis of acute coronary syndrome whose fasting glucose level upon admission was available.

The researchers found that fasting glucose of 100 mg/dL or higher was associated with increased in-hospital mortality compared with subjects whose glucose was below 100 mg/dL. Those whose fasting glucose was 126 or more and who had no known history of diabetes had a higher risk of in-hospital adverse events (odds ratio, 3.37). The fasting glucose level was associated with an increased six-month mortality risk among non-diabetics (odds ratio, 3.03 for a glucose level of 100 to 125 mg/dL and 2.81 for 126 mg/dL or higher) but not diabetics.

"In the present study of patients with acute coronary syndrome, we observed that an elevated fasting admission glucose level was associated with adverse events both in-hospital and at the six-month follow-up point. Furthermore, the risk of adverse events associated with the fasting glucose level at admission was often greatest for non-diabetic patients with acute coronary syndrome," the authors conclude.

The study was partially supported by a grant from Sanofi-Aventis.

Abstract
Full Text (subscription or payment may be required)